title: Budget Impact Model of Sunitinib as First Line Treatment of Metastatic Renal Cell Carcinoma in China.
authors.affiliation: The First People's Hospital of Foshan, Foshan City, China.
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.affiliation: Pfizer China, Shanghai, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Shi
authors.affiliation: School of Pharmacy, University of Florida, Gainesville, FL, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Philadelphia College of Osteopathic Medicine-Georgia Campus, Suwanee, GA, USA.
authors.forename: H
authors.initials: H
authors.lastname: Yin
authors.affiliation: School of Pharmacy, University of Washington, Seattle, WA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.affiliation: Philadelphia College of Osteopathic Medicine-Georgia Campus, Suwanee, GA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Patel
authors.affiliation: Foshan food and drug inspection testing center, Foshan City, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu